Caribou Biosciences, Inc.(CRBU)Earnings, Financials & Key RatiosCaribou Biosciences, Inc. (CRBU) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current cash balance of $12.1 million against a quarterly operating loss of $26.3 million suggests an imminent liquidity shortfall that warrants extreme caution.
Caribou Biosciences, Inc. (CRBU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Caribou Biosciences, Inc. (CRBU) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.26vs $0.33+21.2% | $2Mvs $2M+8.3% |
| Q2 2026 | Mar 5, 2026 | $0.28vs $0.33+15.2% | $4Mvs $2M+78.6% |
| Q4 2025 | Nov 12, 2025 | $0.30vs $0.36+16.7% | $2Mvs $2M+12.3% |
| Q3 2025 | Aug 12, 2025 | $0.35vs $0.40+12.5% | $3Mvs $2M+74.1% |
Recent stock market news and headlines for Caribou Biosciences, Inc. (CRBU)
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the H.C.
Key metrics vs top competitors for Caribou Biosciences, Inc. (CRBU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.92 | $190.43M | -1.21 | 11.66% | -1327.4% | -78.97% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — |
Caribou Biosciences, Inc. (CRBU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Caribou Biosciences, Inc. (CRBU) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 31, 2026·SEC
Mar 5, 2026·SEC
Get notified when CRBU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Caribou Biosciences, Inc. (CRBU) stock FAQ — growth, dividends, profitability & financials explained
Caribou Biosciences, Inc. (CRBU) reported $11.2M in revenue for fiscal year 2025. This represents a 94% increase from $5.8M in 2019.
Caribou Biosciences, Inc. (CRBU) grew revenue by 11.7% over the past year. This is steady growth.
Caribou Biosciences, Inc. (CRBU) reported a net loss of $133.2M for fiscal year 2025.
Caribou Biosciences, Inc. (CRBU) has a return on equity (ROE) of -79.0%. Negative ROE indicates the company is unprofitable.
Caribou Biosciences, Inc. (CRBU) had negative free cash flow of $101.6M in fiscal year 2025, likely due to heavy capital investments.
